FDA Grants Krystal Biotech Platform Technology Designation, Marking Strategic Shift in Gene Therapy Oversight
SHERIDAN, WYOMING – October 15, 2025 – In a pivotal development for the U.S. biotech sector, Krystal Biotech has received the U.S. Food and Drug Administration’s (FDA) second-ever platform technology designation for its non-replicating HSV-1 viral vector—positioning the company as a key early beneficiary of the agency’s emerging regulatory framework for gene therapy platforms.
Validation of a Versatile Gene Delivery Platform
The FDA’s platform designation recognizes Krystal’s HSV-1 vector technology as a “well-understood and reproducible” delivery system capable of supporting multiple gene therapy programs. Analysts at William Blair described Krystal as “poised to be the first major beneficiary” of this program, highlighting the FDA’s confidence in the HSV-1 vector’s cross-program applicability.